Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery

Borbély AN, Figueras Agustí E, Martins A, Bodero L, Raposo Moreira Dias A, Lopez Rivas P, Pina A, Arosio D, Gallinari P, Frese M, Steinkühler C, et al. (2019)
ChemistryOpen 8(6): 737-742.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 1.03 MB
Autor*in
Borbély, Adina NoémiUniBi; Figueras Agustí, EduardUniBi; Martins, Ana; Bodero, Lizeth; Raposo Moreira Dias, Andre; Lopez Rivas, Paula; Pina, Arianna; Arosio, Daniela; Gallinari, Paola; Frese, MarcelUniBi; Steinkühler, Christian; Gennari, Cesare
Alle
Abstract / Bemerkung
RGD-cryptophycin and isoDGR-cryptophycin conjugates were synthetized by combining peptidomimetic integrin ligands and cryptophycin, a highly potent tubulin-binding antimitotic agent across lysosomally cleavable Val-Ala or uncleavable linkers. The conjugates were able to effectively inhibit binding of biotinylated vitronectin to integrin alphavbeta3, showing a binding affinity in the same range as that of the free ligands. The antiproliferative activity of the novel conjugates was evaluated on human melanoma cells M21 and M21-L with different expression levels of integrin alphavbeta3, showing nanomolar potency of all four compounds against both cell lines. Conjugates containing uncleavable linker show reduced activity compared to the corresponding cleavable conjugates, indicating efficient intracellular drug release in the case of cryptophycin-based SMDCs. However, no significant correlation between the in vitro biological activity of the conjugates and the integrin alphavbeta3 expression level was observed, which is presumably due to a non-integrin-mediated uptake. This reveals the complexity of effective and selective alphavbeta3 integrin-mediated drug delivery.
Erscheinungsjahr
2019
Zeitschriftentitel
ChemistryOpen
Band
8
Ausgabe
6
Seite(n)
737-742
ISSN
2191-1363
eISSN
2191-1363
Page URI
https://pub.uni-bielefeld.de/record/2936495

Zitieren

Borbély AN, Figueras Agustí E, Martins A, et al. Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen. 2019;8(6):737-742.
Borbély, A. N., Figueras Agustí, E., Martins, A., Bodero, L., Raposo Moreira Dias, A., Lopez Rivas, P., Pina, A., et al. (2019). Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen, 8(6), 737-742. doi:10.1002/open.201900110
Borbély, A. N., Figueras Agustí, E., Martins, A., Bodero, L., Raposo Moreira Dias, A., Lopez Rivas, P., Pina, A., Arosio, D., Gallinari, P., Frese, M., et al. (2019). Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen 8, 737-742.
Borbély, A.N., et al., 2019. Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen, 8(6), p 737-742.
A.N. Borbély, et al., “Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery”, ChemistryOpen, vol. 8, 2019, pp. 737-742.
Borbély, A.N., Figueras Agustí, E., Martins, A., Bodero, L., Raposo Moreira Dias, A., Lopez Rivas, P., Pina, A., Arosio, D., Gallinari, P., Frese, M., Steinkühler, C., Gennari, C., Piarulli, U., Sewald, N.: Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen. 8, 737-742 (2019).
Borbély, Adina Noémi, Figueras Agustí, Eduard, Martins, Ana, Bodero, Lizeth, Raposo Moreira Dias, Andre, Lopez Rivas, Paula, Pina, Arianna, Arosio, Daniela, Gallinari, Paola, Frese, Marcel, Steinkühler, Christian, Gennari, Cesare, Piarulli, Umberto, and Sewald, Norbert. “Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery”. ChemistryOpen 8.6 (2019): 737-742.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung - Nicht-kommerziell - Keine Bearbeitung 3.0 Unported (CC BY-NC-ND 3.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2020-03-20T12:16:29Z
MD5 Prüfsumme
e8b6497a8008b94ca75b82e615fd4300

52 References

Daten bereitgestellt von Europe PubMed Central.

Antibody-drug conjugates: an emerging concept in cancer therapy.
Chari RV, Miller ML, Widdison WC., Angew. Chem. Int. Ed. Engl. 53(15), 2014
PMID: 24677743
Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A, Goetsch L, Dumontet C, Corvaia N., Nat Rev Drug Discov 16(5), 2017
PMID: 28303026
Drug Delivery in Cancer Therapy, Quo Vadis?
Lu ZR, Qiao P., Mol. Pharm. 15(9), 2018
PMID: 29553749
Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries.
Krall N, Scheuermann J, Neri D., Angew. Chem. Int. Ed. Engl. 52(5), 2013
PMID: 23296451
Small Molecules for Active Targeting in Cancer.
Kue CS, Kamkaew A, Burgess K, Kiew LV, Chung LY, Lee HB., Med Res Rev 36(3), 2016
PMID: 26992114
Ligand-Targeted Drug Delivery.
Srinivasarao M, Low PS., Chem. Rev. 117(19), 2017
PMID: 28898067
Every step of the way: integrins in cancer progression and metastasis.
Hamidi H, Ivaska J., Nat. Rev. Cancer 18(9), 2018
PMID: 30002479
Integrins in cancer: biological implications and therapeutic opportunities.
Desgrosellier JS, Cheresh DA., Nat. Rev. Cancer 10(1), 2010
PMID: 20029421
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
Danhier F, Le Breton A, Preat V., Mol. Pharm. 9(11), 2012
PMID: 22967287
Integrins in angiogenesis and lymphangiogenesis.
Avraamides CJ, Garmy-Susini B, Varner JA., Nat. Rev. Cancer 8(8), 2008
PMID: 18497750
Integrins: roles in cancer development and as treatment targets.
Jin H, Varner J., Br. J. Cancer 90(3), 2004
PMID: 14760364
New perspectives in cell adhesion: RGD and integrins.
Ruoslahti E, Pierschbacher MD., Science 238(4826), 1987
PMID: 2821619
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.
Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, Reuning U, Notni J, Wester HJ, Mas-Moruno C, Spatz J, Geiger B, Kessler H., Sci Rep 7(), 2017
PMID: 28074920
Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides.
Auzzas L, Zanardi F, Battistini L, Burreddu P, Carta P, Rassu G, Curti C, Casiraghi G., Curr. Med. Chem. 17(13), 2010
PMID: 20166941
RGD-mediated delivery of small-molecule drugs.
Katsamakas S, Chatzisideri T, Thysiadis S, Sarli V., Future Med Chem 9(6), 2017
PMID: 28394627
Cancer-targeted delivery systems based on peptides.
Chatzisideri T, Leonidis G, Sarli V., Future Med Chem 10(18), 2018
PMID: 30043641
Isoaspartate-dependent molecular switches for integrin-ligand recognition.
Corti A, Curnis F., J. Cell. Sci. 124(Pt 4), 2011
PMID: 21282473
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin.
Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, Bordignon C, Corti A, Rizzardi GP, Musco G., J. Biol. Chem. 283(28), 2008
PMID: 18480047
Molecular dynamics reveal that isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to promote integrin allostery and activation.
Ghitti M, Spitaleri A, Valentinis B, Mari S, Asperti C, Traversari C, Rizzardi GP, Musco G., Angew. Chem. Int. Ed. Engl. 51(31), 2012
PMID: 22718573
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation.
Nardelli F, Paissoni C, Quilici G, Gori A, Traversari C, Valentinis B, Sacchi A, Corti A, Curnis F, Ghitti M, Musco G., J. Med. Chem. 61(17), 2018
PMID: 29883545
Cyclic RGD-peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
da Ressurreicao AS, Vidu A, Civera M, Belvisi L, Potenza D, Manzoni L, Ongeri S, Gennari C, Piarulli U., Chemistry 15(45), 2009
PMID: 19830748
Cyclic isoDGR peptidomimetics as low-nanomolar αvβ3 integrin ligands.
Mingozzi M, Dal Corso A, Marchini M, Guzzetti I, Civera M, Piarulli U, Arosio D, Belvisi L, Potenza D, Pignataro L, Gennari C., Chemistry 19(11), 2013
PMID: 23424096
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.
Colombo R, Mingozzi M, Belvisi L, Arosio D, Piarulli U, Carenini N, Perego P, Zaffaroni N, De Cesare M, Castiglioni V, Scanziani E, Gennari C., J. Med. Chem. 55(23), 2012
PMID: 23140358
Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C., Chemistry 21(18), 2015
PMID: 25784522
Tumor Targeting with an isoDGR-Drug Conjugate.
Zanella S, Angerani S, Pina A, Lopez Rivas P, Giannini C, Panzeri S, Arosio D, Caruso M, Gasparri F, Fraietta I, Albanese C, Marsiglio A, Pignataro L, Belvisi L, Piarulli U, Gennari C., Chemistry 23(33), 2017
PMID: 28449309
Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3.
Raposo Moreira Dias A, Pina A, Dal Corso A, Arosio D, Belvisi L, Pignataro L, Caruso M, Gennari C., Chemistry 23(58), 2017
PMID: 28816404
Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate.
Raposo Moreira Dias A, Pina A, Dean A, Lerchen HG, Caruso M, Gasparri F, Fraietta I, Troiani S, Arosio D, Belvisi L, Pignataro L, Dal Corso A, Gennari C., Chemistry 25(7), 2018
PMID: 30452790
Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting.
Bodero L, Lopez Rivas P, Korsak B, Hechler T, Pahl A, Muller C, Arosio D, Pignataro L, Gennari C, Piarulli U., Beilstein J Org Chem 14(), 2018
PMID: 29520305
Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Weiss C, Figueras E, Borbely AN, Sewald N., J. Pept. Sci. 23(7-8), 2017
PMID: 28661555
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
D'Agostino G, del Campo J, Mellado B, Izquierdo MA, Minarik T, Cirri L, Marini L, Perez-Gracia JL, Scambia G., Int. J. Gynecol. Cancer 16(1), 2006
PMID: 16445613
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA., Lung Cancer 39(2), 2003
PMID: 12581573
Approaches for the synthesis of functionalized cryptophycins.
Sammet B, Bogner T, Nahrwold M, Weiss C, Sewald N., J. Org. Chem. 75(20), 2010
PMID: 20857920
Recent approaches for the synthesis of modified cryptophycins.
Weiss C, Sammet B, Sewald N., Nat Prod Rep 30(7), 2013
PMID: 23732943
Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis.
Nahrwold M, Weiß C, Bogner T, Mertink F, Conradi J, Sammet B, Palmisano R, Royo Gracia S, Preuße T, Sewald N., J. Med. Chem. 56(5), 2013
PMID: 23387527
The cryptophycins as potent payloads for antibody drug conjugates.
Verma VA, Pillow TH, DePalatis L, Li G, Phillips GL, Polson AG, Raab HE, Spencer S, Zheng B., Bioorg. Med. Chem. Lett. 25(4), 2015
PMID: 25613677
Novel unit B cryptophycin analogues as payloads for targeted therapy.
Figueras E, Borbely A, Ismail M, Frese M, Sewald N., Beilstein J Org Chem 14(), 2018
PMID: 29977395
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J, Moore RE, Moher ED, Munroe JE, Al-awar RS, Hay DA, Varie DL, Zhang TY, Aikins JA, Martinelli MJ, Shih C, Ray JE, Gibson LL, Vasudevan V, Polin L, White K, Kushner J, Simpson C, Pugh S, Corbett TH., Invest New Drugs 23(3), 2005
PMID: 15868377
In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas.
Cazzamalli S, Figueras E, Petho L, Borbely A, Steinkuhler C, Neri D, Sewald N., ACS Omega 3(11), 2018
PMID: 30533574
αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A, Pignataro L, Belvisi L, Gennari C., Curr Top Med Chem 16(3), 2016
PMID: 26126915
Current ADC Linker Chemistry.
Jain N, Smith SW, Ghone S, Tomczuk B., Pharm. Res. 32(11), 2015
PMID: 25759187
An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.
Hatley RJD, Macdonald SJF, Slack RJ, Le J, Ludbrook SB, Lukey PT., Angew. Chem. Int. Ed. Engl. 57(13), 2018
PMID: 28944552
Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.
Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA., J. Clin. Invest. 89(6), 1992
PMID: 1376331
Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells.
Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M., Clin. Exp. Metastasis 19(5), 2002
PMID: 12198771
Influence of αvβ3 integrin on the mechanical properties and the morphology of M21 and K562 cells.
Lange JR, Goldmann WH, Alonso JL., Biochem. Biophys. Res. Commun. 478(3), 2016
PMID: 27553273
Insights into the Binding of Cyclic RGD Peptidomimetics to α5β1 Integrin by using Live-Cell NMR And Computational Studies.
Guzzetti I, Civera M, Vasile F, Arosio D, Tringali C, Piarulli U, Gennari C, Pignataro L, Belvisi L, Potenza D., ChemistryOpen 6(1), 2016
PMID: 28168158
RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways.
Castel S, Pagan R, Mitjans F, Piulats J, Goodman S, Jonczyk A, Huber F, Vilaro S, Reina M., Lab. Invest. 81(12), 2001
PMID: 11742032
Principles in the design of ligand-targeted cancer therapeutics and imaging agents.
Srinivasarao M, Galliford CV, Low PS., Nat Rev Drug Discov 14(3), 2015
PMID: 25698644
Material in PUB:
Dissertation, die diesen PUB Eintrag enthält
Conjugates of Cryptophycin and RGD Peptides for Targeted Cancer Therapy
Borbély AN (2019)
Bielefeld: Universität Bielefeld.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 31275795
PubMed | Europe PMC

Suchen in

Google Scholar